Safety and Feasibility Study of XAF5 Gel for Reduction of Submental Fat
Launched by TOPOKINE THERAPEUTICS, INC. · Nov 15, 2013
Trial Information
Current as of May 25, 2025
Suspended
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria (paraphrased):
- • Adult men and women
- • Must understand and provide informed consent
- • Moderate submental fat (as determined by the clinician)
- • No laxity (looseness) or minimal laxity of submental skin
- • Healthy skin upon which a skin reaction would be visible
- Exclusion Criteria (paraphrased):
- • A clinically significant health problem or recent illness
- • A clinically significant abnormal result on physical exam or laboratory tests
- • Neck or facial hair that would interfere with applying the study drug to submental skin
- • Clinically significant skin disease
- • Body Mass Index (BMI) \>= 40
- • Plan to begin a diet or weight loss regimen during the study
About Topokine Therapeutics, Inc.
Topokine Therapeutics, Inc. is a pioneering biotechnology company focused on developing innovative therapeutics to address unmet medical needs in dermatology and aesthetic medicine. With a commitment to advancing patient care, Topokine leverages its proprietary drug delivery technologies to create targeted treatments for conditions such as hyperhidrosis and other skin disorders. The company is dedicated to conducting robust clinical trials that validate the efficacy and safety of its products, aiming to enhance the quality of life for patients while driving advancements in the field of dermatological therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Michael S Singer, M.D., Ph.D.
Study Director
Topokine Therapeutics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials